Loading clinical trials...
Loading clinical trials...
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Conditions
Interventions
Visbiome Extra Strength
Placebo
Locations
25
United States
31788 Alabama CRS
Birmingham, Alabama, United States
UCLA CARE Center CRS (601)
Los Angeles, California, United States
701 University of California, San Diego AntiViral Research Center CRS
San Diego, California, United States
801 University of California, San Francisco HIV/AIDS CRS
San Francisco, California, United States
University of Colorado Hospital CRS (6101)
Aurora, Colorado, United States
Northwestern University CRS (2701)
Chicago, Illinois, United States
Start Date
April 1, 2016
Primary Completion Date
June 5, 2017
Completion Date
August 28, 2017
Last Updated
January 6, 2020
NCT06660498
NCT06602622
NCT06185452
NCT06902038
NCT04568603
NCT01511809
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions